Clinical Trial: NCT02112916
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-10-21 |
Study Overview
Brief Summary
This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. Bortezomib may help reduce the number of leukemia or lymphoma cells by blocking some of the enzymes needed for cell growth. It may also help chemotherapy work better by making cancer cells more sensitive to the drugs. It is not yet known if giving standard chemotherapy with or without bortezomib is more effective in treating newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Official Title
Conditions
Intervention / Treatment
- Drug: Bortezomib
- Drug: Cyclophosphamide
- Drug: Cytarabine
- Drug: Daunorubicin
- Drug: Daunorubicin Hydrochloride
- Drug: Dexamethasone
- Drug: Doxorubicin
- Drug: Doxorubicin Hydrochloride
- Drug: Etoposide
- Drug: Hydrocortisone Sodium Succinate
- Drug: Ifosfamide
- Drug: Leucovorin Calcium
- Drug: Mercaptopurine
- Drug: Methotrexate
- Drug: Pegaspargase
- Radiation: Radiation Therapy
- Drug: Thioguanine
- Drug: Vincristine
- Drug: Vincristine Sulfate
Other Study ID Numbers
- NCI-2014-00712
- NCI-2014-00712
- s14-01925
- AALL1231
- AALL1231
- U10CA098543
- U10CA180886
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-10-21 |
Study Overview
Brief Summary
This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. Bortezomib may help reduce the number of leukemia or lymphoma cells by blocking some of the enzymes needed for cell growth. It may also help chemotherapy work better by making cancer cells more sensitive to the drugs. It is not yet known if giving standard chemotherapy with or without bortezomib is more effective in treating newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Official Title
Conditions
Intervention / Treatment
- Drug: Bortezomib
- Drug: Cyclophosphamide
- Drug: Cytarabine
- Drug: Daunorubicin
- Drug: Daunorubicin Hydrochloride
- Drug: Dexamethasone
- Drug: Doxorubicin
- Drug: Doxorubicin Hydrochloride
- Drug: Etoposide
- Drug: Hydrocortisone Sodium Succinate
- Drug: Ifosfamide
- Drug: Leucovorin Calcium
- Drug: Mercaptopurine
- Drug: Methotrexate
- Drug: Pegaspargase
- Radiation: Radiation Therapy
- Drug: Thioguanine
- Drug: Vincristine
- Drug: Vincristine Sulfate
Other Study ID Numbers
- NCI-2014-00712
- NCI-2014-00712
- s14-01925
- AALL1231
- AALL1231
- U10CA098543
- U10CA180886